OmegaChoice® Omega-3 Essential Fatty Acids
Product Description
Omega-3 marine essential fatty acids (EFAs) have extensive health benefits, particularly associated with cardiovascular health and cognitive function. Marine sources of omega-3 EFAs are particularly important, because omega-3 fish oil is comprised of polyunsaturated, essential fatty acids that must be obtained from food because they cannot be synthesized by the human body. EPA, eicosapentainoic acid and DHA, docosahexaenoic acid are the two key essential fatty acids in Omega-3. OmegaChoice® marine essential fatty acids are the latest advancement in omega-3 technology exclusively from SourceOne Global Partners.
Market Opportunity
Consumers are seeking natural products for health & wellness in increasing numbers. Scientists, doctors, and the medical community in general all agree on the overwhelming evidence supporting the many health benefits of consuming fish and the Omega-3 essential fatty acids ( EFAs ) so crucial to long lasting health. The trend increases as awareness grows and expands to new demographic groups, areas of the country, and of the world; an improved diet, more exercise, better (natural) foods & nutritional supplementation to improve health.
The rapidly growing demand for more pure and highly concentrated Omega-3 marine EFAs represents an opportunity for SourceOne and the advanced fatty acid expertise of Twin Rivers Technologies. Unequaled technology and Omega-3 production expertise will enable SourceOne to deliver innovation and exceptional value in the natural products market place.
Did you know that most Americans do not get enough Omega-3s?
An adequate dietary supply of Omega-3s can play an important role in overall health throughout all stages of life. Consumers have looked to natural foods to derive a wide range of health benefits from omega-3 fatty acids. EPA and DHA omega-3 is significantly more bioavailable for absorption through cellular membranes found in fish oil than other sources, like flaxseed borage. SourceOne’s OmegaChoice® Omega-3 EPA/DHA provides a highly pure, stable product with less odor and fishy taste, allowing our customers to offer more options and broader applications and, ultimately, greater consumption by consumers.
SourceOne is a leader in introducing new innovations and scientific technologies that help deliver health and wellness through natural products. We are relentless in our pursuit of quality and improvements in nutritional supplements, functional foods and beverages, cosmetics, and animal nutrition that offer more and better solutions to the growing need for healthy and nutritious wellness options. Our dedicated team of global research partners invests heavily in research and development (R&D) and scientific studies. They also work closely with major universities, medical institutions, and clinical research organizations (CROs) to further ensure we have the newest developments keeping SourceOne on the cutting edge of the latest scientific discoveries.
FINA’s intellectual property (IP) portfolio is broad and deep. It is also highly complementary to the relationships SourceOne has already developed with global partners such as Vesifact AG, Baar, Switzerland. The synergies created by these partnerships are directly and immediately applicable to OmegaChoice® Omega-3 EFAs in the various forms and concentrations. The many benefits obtained from these innovations and the IP technology exchange within the SourceOne global partner network will resonate with our client partners and ultimately the consumer focused on health and wellness derived from omega-3.
Compelling examples of these innovations are technologies like the patented VESIsorb® naturally self-assembling association colloidal delivery system and oil to powder technology.
FINA focuses on omega-3s in the natural triglyceride form, which is the form of omega-3 fatty acids naturally found in the food we eat. Produced in a Good Manufacturing Practice (cGMP) facility in Cincinnati, OH to pharmaceutical grade quality standards, FINA’s omega-3 EFAs contain the highest percent EPA and DHA as a triglyceride that is currently available in the global marketplace. Higher purity and better stability with less odor and fishy taste afford broader applications, consumer appeal, and ultimately consumption. FINA’s proprietary Omega-3 technologies and beverage emulsion capabilities provide a strong foundation to meet growing consumer demand for higher omega-3 concentrations in novel forms.
Fish oil supplements come in two forms: the natural triglyceride form or the synthetically manipulated ethyl ester form. It is worth knowing which form you are buying; it is usually not on the label, but you can inquire of the manufacturer.
Did you know the difference is important:
- The triglyceride form of fish oil is natural-- the same form that is found in fish, in contrast with the ethyl ester fo rm of fish oil that does not occur in nature.
- Leading worldwide experts in omega-3 fish oil, such as Artemis Simopoulos, M.D., president of the Center for Genetiucs, Nutrition and Health in Washington, D.C., recommend the natural triglyceride form of fish oil supplements as superior to the ethyl ester form.
- Since it is natural, the triglyceride form of fish oil is more bioavailable and more efficiently utilized by the body, says much research. In one study, 68 of the EPA and 57 percent of the DHA in natural triglyceride omega-3 was absorbed by men, compared with only 20 and 21 percent of the ethyl ester form.
In another study of women, the bioavailability of natural triglyceride type fish oil was double that of ethyl esters. Blood concentrations of EPA and DHA were 52 to 60 percent higher after taking natural triglyceride fish oil than after taking ethyl ester fish oil. “It's apparent that the ethyl ester form of EPA and DHA cannot mimic the physiological activity of natural fish oil in the form of triglycerides, at least in the liver, concluded a recent study on animals.”
The EPA and DHA omega-3 is significantly more bioavailable for absorption through cellular membranes found in fish oil than from flax
seed oil or borage oil. In fact, vegetable oils such as flax and borage do not contain any naturally occurring EPA or DHA at all. Instead, they contain the fatty acid alpha-linolenic, which converts to EPA and DHA when ingested. The conversion, however, is poor at only 4-6%, and is dependent on an individual’s diet and state of wellness.
Clinical Science:
A pharmacokinetic study (single oral dose, crossover) in humans comparing OmegaChoice® 90 Concentrated Omega-3 EPA to the same OmegaChoice® 90 in the VESIsorb® delivery system demonstrated an increase of 567% in peak blood levels (cmax) of EPA. The relative bioavailability calculated using the area under the curve (AUC0-12h) was also increased by 487%.
According to the renowned Mayo Clinic and the American Heart Association, evidence suggests that recommended amounts of the Omega-3 fatty acids slow the buildup of plaque (“hardening of the arteries”), lower triglycerides, and supporting healthy blood pressure thereby reducing the risk factors of heart disease.
Research has demonstrated that omega-3 fatty acids are beneficial for cardiovascular health and reduced risk of cardiovascular disease, and are linked to benefits associated with joint mobility, brain health, fetal development, improved behavior/mood, and anti-aging.
More than 75 studies have demonstrated the effectiveness of Omega-3 for supporting healthy triglyceride levels. Numerous studies have shown that Omega-3 in the triglyceride form are better absorbed and more bioavailable, and OmegaChoice® contains the highest percent EPA and DHA
as a triglyceride currently available in the global marketplace.
Population studies support the value of omega-3. Data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study found
increased adherence to a Mediterranean diet among 2,671 adults with heart attacks lowered mortality rate by 18 percent. A September 2008 Italian study found that daily supplements of omega-3 fatty acids reduced deaths and hospitalizations of people with heart failure. Similar findings were reported by Dutch researchers, who found among adults with previous heart attack, following a Mediterranean diet, along with moderate alcohol consumption and not smoking, lowered all-cause mortality by 40 percent. A study in Diabetes found that omega-3 from fish oil improves glucose uptake in the presence of insulin.
- Singh. Essential fatty acids, DHA and the human brain. Indian Journal of Pediatrics. 2005; 72(3):239–42.
- Peet, et al. Two double–blind placebo–controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001; 49(3):243–251.
- Peet, Horrobin, et al. A dose–ranging study of the effects of ethyl–eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives of General Psychiatry. 2002; 59:913–919.
- James, et al. Dietary n–3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis Rheum. 1997; 27:85–97.
- Puri, et al. The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2004; 70:399–401.
- Theodoratou, et al. Dietary fatty acids and colorectal cancer: a case–control study. American Journal of Epidemiology. 2007; 166(2):181–195.
- Terry, et al. Increased fatty fish consumption may reduce prostate cancer risk. Lancet. 2001; 357(9269):1764–1766.
- Volker, et al. Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol. 2000; 27:2343–2346.
- Cleland, et al. The role of fish oils in the treatment of rheumatoid arthritis. Drugs. 2003; 63:845–853.
- Frangou, et al. Efficacy of ethyl–eicosapentaenoic acid in bipolar depression: randomised double–blind placebo–controlled study. British Journal of Psychiatry. 2006; 188:46–50.
- Zanarini, et al. Omegan–3 Fatty Acid Treatment of Women With Borderline Personality Disorder: A Double–Blind, Placebon–Controlled Pilot Study. Journal of Clinical Psychiatry. 2003; 160:167n–16.
- Genuis, et al. Time for an oil check: the role of essential omegan–3 fatty acids in maternal and pediatric health. Journal of Perinatology. 2006; 26(6):359n–65.
- Gelder, et al. Fish consumption, n–3 fatty acids, and subsequent 5n–y cognitive decline in elderly men: the Zutphen Elderly Study. American Journal of Clinical Nutrition. 2007; 85:1142n–7.
- Hibbeln, et al. Annual Meeting of the American Psychiatric Association; San Francisco. 2003.
- Denburg, et al. Fish oil supplementation in pregnancy modifies neonatal progenitors at birth in infants at risk of atopy. Pediatric Research. 2005; 57(2):276–81.
- Silvers, et al. Randomised double–blind placebo–controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids. 2005; 72(3):211–8.
- Zampelas, et al. Fish Consumption Among Healthy Adults Is Associated With Decreased Levels of Inflammatory Markers Related to Cardiovascular Disease. Journal of the American College of Cardiology. 2005; 46:120n–124. (ATTICA).
- Sinn, et al. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental & Behavioral Pediatrics. 2007; 28(2):82–91.
